Cochrane · systematic review · CD000299
Anti‐tuberculous therapy for maintenance of remission in Crohn's disease
Patton, PH, Parker, CE, MacDonald, JK, et al. · Cochrane Database of Systematic Reviews · 2016 · Cochrane Library
GutAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 3 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Anti‐TB therapy versus placebo for maintenance of remission in Crohn's disease
Population: patients with maintenance of remission in Crohn's disease
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Relapse Anti‐TB therapy vs placebo | RR 0.58 [0.45, 0.75] | 4 studies · 206 participants | Very low Downgraded: risk of bias, imprecision |
Adverse events Anti‐TB therapy vs placebo | RR 2.57 [1.45, 4.55] | 4 studies · 322 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Withdrawals due to adverse events Anti‐TB therapy vs placebo | RR 1.29 [0.6, 2.77] | 4 studies · 322 participants | Very low Downgraded: risk of bias, imprecision |